Chromosomal aberrations in squamous cell carcinomas of the upper aerodigestive tract: biologic insights and clinical opportunities
- 29 July 2005
- journal article
- review article
- Published by Wiley in Journal of Oral Pathology & Medicine
- Vol. 34 (8) , 449-459
- https://doi.org/10.1111/j.1600-0714.2005.00343.x
Abstract
Oncogenesis results from a progressive accumulation of genetic aberrations consequent to a complex interplay between carcinogenic factors and innate infidelity of DNA surveillance mechanisms. Although the development of genetic aberrations is random, those conferring survival advantages are selected for in a Darwinian manner, thus allowing continuous adaptation to selection pressures. Chromosomal aberrations are a prominent manifestation of genetic damage, which can be closely linked with tumor behavior and outcome as exemplified by curative treatment of chronic myelogenous leukemia resulting from targeting the BCR-ABL translocation. In the case of head and neck squamous cell carcinomas (HNSCC), chromosomal changes are detectable at all stages of tumor development, providing excellent opportunities for genomic prognostication and therapy. Several studies have shown that the overall genomic profile of HNSCC is highly consistent, but individual tumors vary significantly in their complement of genetic alterations, thereby confounding clinical correlation. The application of modern genetic and bioinformatic analytic approaches has facilitated the identification of critical genomic changes in HNSCC, many of which have been linked to clinical outcome. These genetic aberrations represent excellent targets for novel therapeutics, but require validation. The initiation of phase III trials evaluating the therapeutic utility of genetic aberrations suggests a promising future for genome-based treatment of HNSCC.Keywords
This publication has 103 references indexed in Scilit:
- Cancer genes and the pathways they controlNature Medicine, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Genome-Wide Profiling of Papillary Thyroid Cancer Identifies MUC1 as an Independent Prognostic MarkerCancer Research, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Prognostic implications of loss of heterozygosity at 8p21 and 9p21 in head and neck squamous cell carcinomaInternational Journal of Cancer, 2004
- ‘Targeting’ the epidermal growth factor receptor tyrosine kinase with gefitinib (Iressa®) in non-small cell lung cancer (NSCLC)Seminars in Cancer Biology, 2004
- Mutational Analysis of the Tyrosine Kinome in Colorectal CancersScience, 2003
- Targeting epidermal growth factor receptor in head and neck cancerHead & Neck, 2002
- Amplification of the 3q26.3 Locus Is Associated with Progression to Invasive Cancer and Is a Negative Prognostic Factor in Head and Neck Squamous Cell CarcinomasThe American Journal of Pathology, 2002
- DNMT1 and DNMT3b cooperate to silence genes in human cancer cellsNature, 2002